MVC-COV1901

A COVID-19 candidate protein subunit vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

2
Supporting references
0
Contradictory references
12
Clinical trials

General information

MVC-COV1901 is a COVID-19 candidate protein subunit vaccine being developed by Medigen Vaccine Biologics Corporation/NIAID/Dynavax. It is based on a prefusion SARS-CoV-2 spike immunogen with CpG 1018 (a Th1-biasing synthetic toll-like receptor 9 agonist) and aluminum hydroxide serving as adjuvants (Kuo et al., 2020). Currently, this COVID-19 candidate vaccine is being evaluated in Phase I and Phase II clinical trials. 


Synonyms

S-2P subunit vaccine


Supporting references

Link Tested on Impact factor Notes Publication date DB entry date
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
Protein factor Animal model Mixed substance
HEK293-hACE2 cells; Vero E6 cells; female BALB/c and C57BL/6 mice; Wuhan-Hu-1 strain SARS-CoV-2 spike protein pseudovirus; live SARS-CoV-2 (hCoV-19/Taiwan/CGMH-CGU-01/2020, GenBank accession MT192759)

Used with CpG 1018 (a Th1-biasing synthetic toll-like receptor 9 agonist) and aluminum hydroxide as adjuvants, the candidate vaccine induced high titer of neutralizing antibodies against pseudotyped virus or live SARS-CoV-2 in sera of immunized mice. No serious adverse reactions were noted.

Nov/29/2020 Nov/29/2020
Draft landscape of COVID-19 candidate vaccines healthy adults Jul/28/2020 Aug/06/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05197153 A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 Not yet recruiting Phase 2 Jan/01/2022 Dec/01/2022
NCT05132855 The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine Active, not recruiting Phase 1|Phase 2 Nov/30/2021 Apr/01/2023
NCT05011526 A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults Active, not recruiting Phase 3 Oct/08/2021 Jun/01/2022
NCT05097053 A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19 Recruiting Phase 4 Oct/07/2021 Jul/01/2022
NCT05079633 A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults Active, not recruiting Phase 4 Sep/30/2021 Jun/01/2022
NCT05054621 Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Recruiting Phase 2 Sep/15/2021 Aug/31/2022
NCT05038618 A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study Active, not recruiting Phase 2 Aug/02/2021 Feb/01/2022
NCT04951388 A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents Active, not recruiting Phase 2 Jul/22/2021 May/01/2022
NCT05048849 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study Active, not recruiting Phase 2 Jul/19/2021 Mar/01/2022
NCT04822025 A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults Active, not recruiting Phase 2 May/20/2021 Jan/01/2022
NCT04695652 A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult Active, not recruiting Phase 2 Dec/30/2020 Jun/01/2022
NCT04487210 A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19 Active, not recruiting Phase 1 Oct/07/2020 Dec/30/2021